Ondek raises capital to develop new treatment for childhood allergy

Ondek, the Australian biotechnology company founded by Nobel Laureate Professor Barry Marshall, today announced it raised A$3.59 million in equity funding from professional and high-net-worth investors to support his work to develop a new treatment for childhood allergy.

Ondek is seeking to develop a new immunotherapy based on the bacterium Helicobacter pylori.  The company has patented a killed derivative of H. pylori to be developed as a natural and safe immunotherapy named ImmBALANCE®.

Read more